Comparative Pharmacology
Head-to-head clinical analysis: ROZLYTREK versus TEPMETKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROZLYTREK versus TEPMETKO.
ROZLYTREK vs TEPMETKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Entrectinib is a potent inhibitor of tropomyosin receptor tyrosine kinases (TRK) A, B, and C, and also inhibits ROS1 and ALK. It blocks downstream signaling pathways including MAPK, PI3K/AKT, and PLCγ, leading to apoptosis and reduced tumor growth in cancers with NTRK or ROS1 fusions.
Tepotinib is a highly selective, ATP-competitive inhibitor of the mesenchymal-epithelial transition (MET) receptor tyrosine kinase, including the MET exon 14 skipping variant. It inhibits MET phosphorylation and downstream signaling pathways, thereby reducing tumor cell proliferation and migration.
200 mg orally once daily with or without food.
450 mg orally once daily with food.
None Documented
None Documented
Terminal half-life approximately 24 hours; supports once-daily dosing, steady-state reached in ~5 days.
Terminal elimination half-life approximately 12-15 hours in patients, supporting twice-daily dosing.
Primarily hepatic metabolism via CYP3A4; 63% of dose recovered in feces (mostly as metabolites), 18% in urine (9% unchanged).
Primarily fecal (≥80% of absorbed dose), with renal excretion accounting for <5% as unchanged drug.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor